Stratification of patients for IDO1 inhibitor treatment based on IDO1 expression and activity (based on Trp and Trp-derived metabolites, such as Kyn and Kyn catabolite levels) in the tumour tissues and body fluids therefore is critical (Fig. 2d). This evidence concerns the gene IDO1 and neoplasm.